Natco Pharma clears legal hurdle to launch generic version of Copaxone

21 Apr 2014 Evaluate

The US Supreme Court Chief Justice Roberts has denied Teva’s application for an injunction seeking to prevent launch of a generic version of Copaxone pending the Supreme Court’s decision on Teva’s appeal. This has cleared legal hurdle for Mylan & Natco Pharma to launch the same at market formation. This is the second time that the Chief Justice has denied Teva’s request for such an injunction.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.

Natco Pharma Share Price

895.90 -12.20 (-1.34%)
29-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.50
Dr. Reddys Lab 1268.60
Cipla 1494.40
Zydus Lifesciences 904.00
Lupin 2079.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×